Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Citi
QuintilesIMS
Harvard Business School
McKinsey
Argus Health
Farmers Insurance
Cerilliant
Chubb

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,935,946

« Back to Dashboard

Which drugs does patent 5,935,946 protect, and when does it expire?


Patent 5,935,946 protects VIREAD, ATRIPLA, COMPLERA, STRIBILD, and TRUVADA, and is included in six NDAs. There have been zero Paragraph IV challenges on Truvada, Complera, Viread, and .

Protection for VIREAD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in twenty countries.

Summary for Patent: 5,935,946

Title: Nucleotide analog composition and synthesis method
Abstract:The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxyphosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods.
Inventor(s): Munger, Jr.; John D. (Alviso, CA), Rohloff; John C. (Mountain View, CA), Schultze; Lisa M. (San Carlos, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:08/900,752
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences IncVIREADtenofovir disoproxil fumaratePOWDER;ORAL022577-001Jan 18, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
GileadATRIPLAefavirenz; emtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021937-001Jul 12, 2006RXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncCOMPLERAemtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarateTABLET;ORAL202123-001Aug 10, 2011RXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncSTRIBILDcobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarateTABLET;ORAL203100-001Aug 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-002Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-003Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-004Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-002Jan 18, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-003Jan 18, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,935,946

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria228526► Subscribe
Austria288914► Subscribe
Austria305009► Subscribe
Australia756793► Subscribe
Australia8582798► Subscribe
Brazil9811045► Subscribe
Canada2298059► Subscribe
Canada2605226► Subscribe
China100383148► Subscribe
China100420443► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Farmers Insurance
Daiichi Sankyo
Harvard Business School
Queensland Health
Express Scripts
Teva
Julphar
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot